Aid Nutromics 39 Co Founder And Ceo Peter Vranes Is Developinga Wearable Diagnostic Platform That Uses Dna Technology To Enable Tracking For Multiple Targets In The Human Body Usinga Single Patch This First Of Its Kind Botha Proven Work On Sensor Will Provide Clinicians Patients With Continuous Real Time Information Ranging From Hard Dose Drugs News Today : Breaking News, Live Updates & Top Stories | Vimarsana

MELBOURNE, Australia and SAN DIEGO, Sept. 8, 2022 /PRNewswire/ Global MedTech start-up Nutromics has raised an additional US $14 million for its wearable diagnostic platform. This transformative funding is key to Nutromics' continued expansion across Australia and the United States. Strategic investors included Dexcom Ventures, VU Venture Partners, and Artesian Investments. This funding demonstrates a resounding level of investor confidence in the potential of Nutromics' technology, which will tackle some of healthcare's most challenging conditions through the power of continuous diagnostic monitoring. Nutromics plans to raise significantly more funding in 2023 following in-vivo clinical studies. "We are aiming to cause a paradigm shift in diagnostic healthcare by essentially developing a lab-on-a-patch. A lack of timely and continuous diagnostic insights can strongly impact outcomes when dealing with critical disease states. With this strategic industry and VC inves ....

United States , Peter Vranes , Dexcom Ventures , Hitesh Mehta , Ustralia And San Diego , Sept 8 , 022 Prnewswire Global Medtech Start Up Nutromics Has Raised An Additional Us 14 Million For Its Wearable Diagnostic Platform This Transformative Funding Is Key To 39 Continued Expansion Across Australia And The United States Strategic Investors Included Dexcom Ventures , U Venture Partners , Nd Artesian Investments This Funding Demonstratesa Resounding Level Of Investor Confidence In The Potential Nutromics 39 Technology , Hich Will Tackle Some Of Healthcare 39s Most Challenging Conditions Through The Power Continuous Diagnostic Monitoring Nutromics Plans To Raise Significantly More Funding In 2023 Following Vivo Clinical Studies Quot We Are Aiming Causea Paradigm Shift By Essentially Developinga Lab Ona Patcha Lack Timely And Insights Can Strongly Impact Outcomes When Dealing With Critical Disease States This Strategic Industry Vc Investment Us , E See More Confidence In Our Technology And Hope To Accelerate Growth , S The Need For Our Platform In Lab Diagnostic Space Is Urgent Quot , Aid Nutromics 39 Co Founder And Ceo Peter Vranes Is Developinga Wearable Diagnostic Platform That Uses Dna Technology To Enable Tracking For Multiple Targets In The Human Body Usinga Single Patch This First Of Its Kind Botha Proven Work On Sensor Will Provide Clinicians Patients With Continuous Real Time Information Ranging From Hard Dose Drugs , Ike Vancomycin , O Biological Markers For Conditions Such As Kidney Disease Nutromics Was Founded In 2017 And Including This Recent Acceleration Round Has Raised Over Us 20 Million To Date Its Ground Breaking Wearable Diagnostic Platform Latest Of Funding Will Support An Expansion Clinical Studies , Xpansion Ofr Ampd Team And Investment Across Both Australian United States Hubs The Company 39s Exponential Growth Over Last Year , Long With This Latest Round Of Funding Brings Nutromics One Step Closer To Realizing Their Vision Ofa World Zero Preventable Deaths About Founded In 2017 By Peter Vranes Ceo And Hitesh Mehta Coo , Utromics Is Ona Mission To Revolutionize Healthcare Through Continuous Diagnostic Monitoring , Itha Vision Fora World With Zero Preventable Deaths Through Personalized And Timely Diagnostic Insights Nutromics Is Developinga Wearable Platform Combining Microneedles That Provide Pain Free Access To Interstitial Fluid , Ust Under The Skin , Nd Dna Sensor Technology Nutromics Will Complete World First In Human Clinical Studies Of Its Sensors 2022 , S Well As Its Integrated Alpha Prototype Device Source Nutromics ,